key: cord-1011949-ui9u73fv
authors: Li, Jun‐Ying; Wang, Hong‐Fei; Yin, Ping; Li, Di; Wang, Di‐Le; Peng, Peng; Wang, Wei‐Hua; Wang, Lan; Yuan, Xiao‐Wei; Xie, Jin‐Yuan; Zhou, Fan; Xiong, Nian; Shao, Feng; Wang, Chun‐Xiu; Tong, Xiang; Ye, Hao; Wan, Wen‐Jun; Liu, Ben‐De; Li, Wen‐Zhu; Li, Qian; Tang, Liang V.; Hu, Yu; Lip, Gregory Y. H.
title: Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID‐19 patients: A multicenter retrospective study
date: 2021-02-24
journal: J Thromb Haemost
DOI: 10.1111/jth.15261
sha: 76323a8f1f969a07147b32a032edab7f02684eb6
doc_id: 1011949
cord_uid: ui9u73fv

BACKGROUND: High incidence of asymptomatic venous thromboembolism (VTE) has been observed in severe COVID‐19 patients, but the characteristics of symptomatic VTE in general COVID‐19 patients have not been described. OBJECTIVES: To comprehensively explore the prevalence and reliable risk prediction for VTE in COVID‐19 patients. METHODS/RESULTS: This retrospective study enrolled all COVID‐19 patients with a subsequent VTE in 16 centers in China from January 1 to March 31, 2020. A total of 2779 patients were confirmed with COVID‐19. In comparison to 23,434 non‐COVID‐19 medical inpatients, the odds ratios (ORs) for developing symptomatic VTE in severe and non‐severe hospitalized COVID‐19 patients were 5.94 (95% confidence interval [CI] 3.91–10.09) and 2.79 (95% CI 1.43–5.60), respectively. When 104 VTE cases and 208 non‐VTE cases were compared, pulmonary embolism cases had a higher rate for in‐hospital death (OR 6.74, 95% CI 2.18–20.81). VTE developed at a median of 21 days (interquartile range 13.25–31) since onset. Independent factors for VTE were advancing age, cancer, longer interval from symptom onset to admission, lower fibrinogen and higher D‐dimer on admission, and D‐dimer increment (DI) ≥1.5‐fold; of these, DI ≥1.5‐fold had the most significant association (OR 14.18, 95% CI 6.25–32.18, p = 2.23 × 10(−10)). A novel model consisting of three simple coagulation variables (fibrinogen and D‐dimer levels on admission, and DI ≥1.5‐fold) showed good prediction for symptomatic VTE (area under the curve 0.865, 95% CI 0.822–0.907, sensitivity 0.930, specificity 0.710). CONCLUSIONS: There is an excess risk of VTE in hospitalized COVID‐19 patients. This novel model can aid early identification of patients who are at high risk for VTE.

Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), occurs in approximately 1 out of 1000 individuals in the general population, but is often secondary to other clinical conditions. 1 During the coronavirus disease 2019 (COVID-19) pandemic, high prevalence of DVT was observed in severe COVID-19 patients, especially in the intensive care unit (ICU). [2] [3] [4] High prevalence of incident thrombosis in small and mid-sized pulmonary arteries has been demonstrated in clinicopathologic case series, despite thromboprophylaxis. 5, 6 Most VTE are asymptomatic and whether they are the cause of death or only concurrent events remains controversial. 7 On the other hand, COVID-19 patients at high risk for VTE are also at high risk for bleeding, and sometimes catastrophic intracranial hemorrhage may occur. 8 Therefore, anticoagulation may potentially be harmful, and it would be important to distinguish those who will develop thromboses in hospitalized COVID-19 patients. 9 The prevalence, clinical characteristics, and risk factors for clinically relevant symptomatic VTE in hospitalized COVID-19 patients continue to be debated, and there remains a lack of satisfactory VTE risk prediction in these patients. Given this context, we performed a multicenter study to explore the prevalence, risk factors, and prediction models for symptomatic VTE in hospitalized COVID-19 patients.

• There is an excess risk of venous thromboembolism (VTE) in severe and non-severe hospitalized COVID-19 patients.

• Risk factors are aging, cancer, longer duration of symptoms prior to admission, lower fibrinogen, higher Ddimer, and D-dimer increment.

• D-dimer increment≥1.5-fold has the most significant association with VTE in hospitalized COVID-19 patients.

• A novel experimental model is a promising approach for symptomatic VTE prediction.

The flowchart for the study is summarized in Figure S1 in supporting information. This multicenter, retrospective, observational study was conducted in 16 centers including Wuhan, China, the first epicenter of the COVID-19 pandemic in the world.

First, we investigated the absolute and relative risk for symptomatic VTE in hospitalized COVID-19 patients using a retrospective cohort study design, with data from 3 of the 16 

For the case-control study, data on demographic, clinical, laboratory, chest radiographs or CT scan, treatment, outcome, and VTE and bleeding events were extracted from electronic medical records of each center. Missing or uncertain records were clarified through communication with involved clinicians or patients. All data were checked by two investigators (LVT and HFW), and any difference in interpretation was adjudicated by a third clinician (WZL).

COVID-19 was confirmed by the laboratory tests of SARS-CoV-2 RNA as described previously. 11 thrombosis and visceral VTE were not examined. According to the ISTH criteria, major bleeding following anticoagulation was defined as clinically overt bleeding accompanied by a decrease in the hemoglobin level of at least 20 g/L or transfusion of at least 2 U of packed red blood cells, occurring at a critical site (such as intracranial), or resulting in death. In this study, D-dimer increment (DI) was defined as D-dimer level on day 4 to day 6 divided by that on day 1 to day 3 following hospitalization.

Three clinical risk assessment models (the Padua model, the Improve model, and the Geneva model) for VTE in hospitalized medical patients were evaluated for each participant. 13,14 A "6-factor model" was tentatively defined as the combination of six independent variables for VTE in the final logistic regression model: age, cancer, interval from COVID-19 onset to admission, fibrinogen concentration and D-dimer level on admission, and D-dimer increment ≥1.5-fold.

A simplified "3-factor model," or "Wuhan score" was tentatively defined as the model consisting of the three coagulation variables (fibrinogen and D-dimer on admission, and DI ≥1.5-fold) that were significantly associated with symptomatic VTE in COVID-19 patients described in the analysis below. patients ( Figure 1B ).

We compared 104 VTE cases and 208 disease-severity-matched controls without symptomatic VTE from 16 centers ( Figure S1 and Table S2 in supporting information.

The timeline for clinical outcomes from COVID-19 onset is sum- Median times from COVID-19 onset to virus clearance were similar in the two groups (P = .53).

Possible factors and prediction models related to VTE in hospitalized COVID-19 patients were assessed (Table S3 ). The proportion of Padua score ≥4, Improve score ≥3, Geneva score ≥3, and D-dimer increment ≥1.5-fold were higher in the VTE cases than in non-VTE

On multivariable analysis ( Kaplan-Meier curves showed a higher cumulative symptomatic VTE incidence in hospitalized COVID-19 patients with Padua score ≥4, Improve score ≥3, Geneva score ≥3, and D-dimer increment ≥1.5fold ( Figure 3A-D) . Multivariable analysis using a Cox proportionalhazard model also indicated that D-dimer increment ≥1.5-fold had the most significant association with symptomatic VTE ( 

To our knowledge, this is the largest multicenter study that systematically investigated the risk of, and predicting factors for, sympto- Several other studies and case series on incidence of VTE in COVID-19 patients have been published. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] The reported incidence of VTE in these cohorts varied widely (4.1% to 85.4%) due

to the different characteristics of study population, different diagnostic methods, and various thromboprophylaxis modalities. Most of the studies enrolled critically ill patients and employed a screening strategy with ultrasonography. Asymptomatic VTE events were also commonly included, which accounted for 65.2% to 87.8% of the total VTE events. Therefore, strikingly high rates of VTE in hospitalized COVID-19 patients were observed.

In contrast, we focused on symptomatic VTE, which was more clinically relevant and has always been used as the primary outcome in clinical trials. Indeed, asymptomatic VTE is widely prevalent in special populations, such as patients suffering from acute infectious diseases or cancer, and those who are critically ill, even before hospitalization. Some studies suggested that less than 5% of the asymptomatic VTE could progress to a clinically symptomatic event. Thus, asymptomatic DVT is associated with a low risk of recurrence as well as a low risk of post-thrombotic syndrome, and long-term mortality in asymptomatic DVT is broadly comparable to that seen in non-DVT patients. 29 Moreover, anticoagulant prophylaxis confers an absolute risk reduction in asymptomatic VTE events of only 2.6%, but results in significantly increased risk in major bleeding. 30 In contrast, there is also evidence that asymptomatic DVT is associated with increased short-term mortality in medical patients. 31 In early studies on COVID-19, the most typical finding was a higher D-dimer concentration on admission in patients with VTE than that in those without VTE. 18, 21, 26 Therefore, D-dimer on admission was considered a diagnostic marker for VTE in COVID- 19. 40 Nevertheless, D-dimer has a low specificity, and we have observed that many patients with a high D-dimer level would not necessarily develop a symptomatic VTE if the level kept stable or increased slowly. In contrast, in COVID-19 patients who are likely to develop a symptomatic VTE, the D-dimer will rise sharply within the first week during hospitalization.

Because the duration from admission to symptomatic VTE ranged from 8 to 20.75 days (Figure 2) , we proposed using a D-dimer increment of ≥1.5-fold increase, from day 1-3 to day 4-6 following hospitalization. Indeed, such a D-dimer increment was the most significant risk factor for developing symptomatic VTE using multivariable analysis. Additionally, D-dimer increment improved the specificity significantly, and predictive accuracy for VTE prediction comparing single clinical or laboratory variables ( Figure 4 ).

The Padua score, the IMPROVE model, and the Geneva risk score are robust risk assessment models evaluating VTE risk in hospitalized medical patients (Table S5 in supporting information). 12 Consistent with previous findings, the above three models were also associated with developing symptomatic VTE in hospitalized COVID-19

patients. They are clinical assessment models that included various demographic and clinical characteristics. All these clinical variables will ultimately contribute to a hypercoagulable state, which will be reflected by coagulation variables. Therefore, we proposed a simple "3-factor score" (Wuhan score) consisting of three independent coagulation predictors for VTE identified using multivariable analysis: 

There is an excess risk of symptomatic VTE in severe and nonsevere hospitalized COVID-19 patients. New-onset PE increased in-hospital deaths, and three coagulation variables (fibrinogen and D-dimer on admission, and DI ≥1.5-fold) predicted symptomatic VTE in hospitalized COVID-19 patients. This "3-factor" model can aid in early identification of COVID-19 patients who are at high risk for symptomatic VTE.

We wish to acknowledge the dedication, commitment, and sacrifice of the staff, providers, and personnel in each center through the local COVID-19 crisis and express our profound sadness about the suffering and loss of our patients, their families, and our community.

Special thanks go to the participants included in this report. 

Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study

Coagulation abnormalities and thrombosis in patients with COVID-19

Prevention and treatment of venous thromboembolism associated with coronavirus disease 2019 infection: a consensus statement before guidelines

Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19

Acute pulmonary embolism and COVID-19 pneumonia: a random association?

Pulmonary arterial thrombosis in COVID-19 with fatal outcome

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Catastrophic intracranial hemorrhage in two critically ill patients with COVID-19. Neurocrit Care

Hospital-based use of thromboprophylaxis in patients with COVID-19

Association of intraoperative hypotension with acute kidney injury after noncardiac surgery in patients younger than 60 years old

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Risk assessment models for venous thromboembolism in acutely ill medical patients. A systematic review

Validation of risk assessment models predicting venous thromboembolism in acutely ill medical inpatients: a cohort study

Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-Dimer levels

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

D-dimer in patients infected with COVID-19 and suspected pulmonary embolism

Deep vein thrombosis in hospitalized patients with coronavirus disease

China: prevalence, risk factors, and outcome

Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Comparison of venous thromboembolism risks between COVID-19 pneumonia and communityacquired pneumonia patients

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Pulmonary embolism in patients with Covid-19 pneumonia

Thrombotic risk in COVID-19: a case series and case-control study

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis

Asymptomatic lower extremity deep vein thrombosis-clinical characteristics, management strategies, and long-term outcomes

Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis

Asymptomatic deep vein thrombosis is associated with an increased risk of death: insights from the APEX Trial

PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients

Asymptomatic venous thrombosis in cancer patients-a problem often overlooked. Results of a retrospective and prospective study

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

COVID-19 and its implications for thrombosis and anticoagulation

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report

COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection

Scientific and standardization committee communication: clinical guidance on the diagnosis, prevention and treatment of VTE in hospitalized patients with COVID-19

D-dimer cut-off points and risk of venous thromboembolism in adult hospitalized patients with COVID-19

Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study

All authors participated in interpretation of data, critically revised the manuscript for important intellectual content, and gave final approval for the version to be published. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Liang V. Tang https://orcid.org/0000-0002-3253-0220